NEW YORK (GenomeWeb) – Agendia said Tuesday that updated guidelines from the European Group on Tumor Markers named the firm's MammaPrint 70-gene signature test "as the first and currently the only multigene test of its kind deemed to have level 1A evidence for its clinical use."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.